Horinouchi H - Search Results

1

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. Travis WD, et al. Among authors: horinouchi h. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005. Epub 2020 Jan 28. J Thorac Oncol. 2020. PMID: 32004713 Free PMC article. Review.

2

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T. Asahina H, et al. Among authors: horinouchi h. Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.008. Epub 2011 Sep 3. Clin Lung Cancer. 2012. PMID: 21890422

3

Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer.

Minami-Shimmyo Y, Ohe Y, Yamamoto S, Sumi M, Nokihara H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Tamura T. Minami-Shimmyo Y, et al. Among authors: horinouchi h. J Thorac Oncol. 2012 Jan;7(1):177-82. doi: 10.1097/JTO.0b013e31823c4c07. J Thorac Oncol. 2012. PMID: 22134071 Free article.

4

Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.

Horinouchi H, Sekine I, Sumi M, Noda K, Goto K, Mori K, Tamura T. Horinouchi H, et al. Cancer Sci. 2013 Jan;104(1):93-7. doi: 10.1111/cas.12028. Epub 2012 Nov 8. Cancer Sci. 2013. PMID: 23004347 Free PMC article. Clinical Trial.

5

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y. Kitazono S, et al. Among authors: horinouchi h. Clin Lung Cancer. 2015 Sep;16(5):385-90. doi: 10.1016/j.cllc.2015.03.008. Epub 2015 Apr 4. Clin Lung Cancer. 2015. PMID: 25937270

6

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.

Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T, Ohe Y. Yagishita S, et al. Among authors: horinouchi h. Cancer Sci. 2015 Oct;106(10):1402-7. doi: 10.1111/cas.12740. Epub 2015 Aug 18. Cancer Sci. 2015. PMID: 26177347 Free PMC article.

7

The prospect of patritumab for treating non-small cell lung cancer.

Horinouchi H. Horinouchi H. Expert Opin Biol Ther. 2016 Dec;16(12):1549-1555. doi: 10.1080/14712598.2016.1249846. Epub 2016 Nov 3. Expert Opin Biol Ther. 2016. PMID: 27744717 Review.

8

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.

Okuma HS, Horinouchi H, Kitahara S, Asao T, Sunami K, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y. Okuma HS, et al. Among authors: horinouchi h. Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25. Clin Lung Cancer. 2017. PMID: 27867001 Free article.

9

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions.

Ohara S, Kanda S, Okuma H, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Ito Y, Yamamoto N, Usui K, Homma S, Ohe Y. Ohara S, et al. Among authors: horinouchi h. Jpn J Clin Oncol. 2018 Jan 1;48(1):82-88. doi: 10.1093/jjco/hyx153. Jpn J Clin Oncol. 2018. PMID: 29136177

10

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.

Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y. Sekine K, et al. Among authors: horinouchi h. Lung Cancer. 2018 Oct;124:179-188. doi: 10.1016/j.lungcan.2018.08.012. Epub 2018 Aug 13. Lung Cancer. 2018. PMID: 30268458 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters